Randy Talbott Email & Phone Number

Greater New York City Area

Biotechnology / Venture Capital Company Consultant – built client relationships through oral and written presentations. Diverse subject matter include T-cell stimulation (cancer Rx) or suppression (autoimmune diseases), organoid High Throughput Screen development, murine tumor model strengths and weaknesses and clinical development of tumor suppressor modulators.

Princeton, Nj

Lentivirus Target Validation Core Laboratory – responsible for lentivirus construction, production, viral titer/storage and cell transduction for use in loss of function studies. Developed methodologies to identify and validate oncology drug discovery targets using chromophore co-expressing lentivirus shRNA products. Constructed lentivirus libraries expressing selected fluorescent proteins and measured the effects of promoter strength on both cell viability and assay robustness. Validated assay with chromophore-lentivirus constructs co-expressing RAS shRNA by monitoring the ability to inhibit cell growth in RAS dependent human tumor cell lines. Determined specificity of target knockdown by rescuing cells with a second chromophore containing lentivirus co-expressing a RAS transgene made resistant to shRNA knockdown. Used chromophore-lentivirus methodology to identify and validate targets leading to initiation of oncology exploratory programs.

Princeton, Nj

XIAP/IAP Antagonist Biology Co-Chair - developed and executed methodologies to make program competitive. Performed protein binding experiments necessary to validate Fluorescent Polarization (FP) binding assays capable of measuring antagonist – target protein interactions. Successfully transferred assays to both internal and external collaborators. Developed an in-vitro caspase-3 activation assay measuring compound-antagonist protein interactions capable of restoring caspase-3 activity. Designed & acquired recombinant plasmid, peptide & protein reagents enabling implementation of full deck High Throughput Screen using validated antagonist/protein binding assay. Performed studies demonstrating compound treatment modulated cytokine expression as well as dendritic and T-cell activation marker levels. Developed cell-based apoptosis assay panel and measured cellular effects of antagonists on Type I (sensitive) & Type II (resistant) apoptotic pathways; measured cellular activity of BMS & competitor compounds as single agent treatment or in combination w/ other chemotherapeutics in tumor cell lines having defined target protein profiles. Collaborated with LVL-Biology scientists to develop relevant in-vivo tumor models capable of measuring compound anti-tumor activities; successfully designed and executed in vivo PD biomarker studies; developed pharmaco-dynamic and predictive biomarker hypotheses based on apoptotic pathway gene transcription patterns. Designed and performed ELISA, FRET & AlphaScreen binding assays capable of measuring compound-antagonist interactions. Collaborated with scientists from CADD, Molecular Enzymology & Macromolecular Crystallography to develop structural models capable of aiding SAR efforts. Assembled efficacy, toxicity and biomarker data packages and communicated findings to key stakeholders. Explored external opportunities and wrote innovation grant proposals to fund clinical biomarker development.

Princeton, Nj

MDM2 Ubiquitin Ligase Inhibitor Biology Co-Chair - obtained legal review, created an effective IP workaround discovery flow scheme, performed validation studies using siRNA technology, developed cell-based high throughput & cytotoxicity screens as well as implemented & evaluated candidate small molecule inhibitors in L-V Biology assays; succeeded in designing & performing cell-based and biochemical studies to understand inhibitor mechanism of action; developed selectivity assays to determine compound/target specificity versus other ubiquitination pathway enzymes; provided intellectual input towards exploring feasibility of establishing potential research collaborations with Columbia University scientists (B. Stockwell, C. Prives); presented Ubiquitin Ligase Inhibitor Program in both internal & external forums. BMS G Protein-Coupled Receptor Focus Group Co-Chair - Actively represented LVL Biology in the BMS-GPCR Focus Group (Formerly GPCR Target Class Team). Maintained and enhanced communication within the BMS-GPCR community through scheduling and participation in quarterly focus group meetings.New Oncology Literature Target Identification Explored feasibility of establishing program to identify inhibitors of Survivin/XIAP interaction.Explored feasibility of establishing program to identify TNF-like weak inducer of apoptosis (TWEAK) receptor FN14 & scavenger receptor CD163 antagonists; profiled tumor cell panel for FN14 & CD163 cell-surface expression; explored connection between FN14 &/or CD163 antagonism and tumor cell death.Explored activity of stapled peptides in Bcl antagonist program assays. Efforts included performing protein binding experiments necessary to develop, implement and validate a FP Binding Assay capable of measuring peptide - protein interactions; measuring cellular activities of stapled peptides in tumor cell lines with defined Bcl family member profiles.

Princeton, Nj

BMS-Exelixis DWG member - Evaluated scientific and pharmaceutical applicability of pursuing RanBP2 as a drug discovery target and presented findings to the Exelixis DWG. Efforts resulted in management selecting RanBP2 for further validation as an Oncology target. Formulated and communicated strategy to understand mechanism of action of RanBP2 inhibition using reagents and cell lines currently available in L-V Biology. Initiated siRNA validation studies to help drive Go/No Go decision for RanBP2 target selection. Novel orphan GPCRs DWG member – Proactive member championing the identification and validation of novel GPCR gene products for Oncology indications. Worked with PRI scientist to gather intellectual property of selected novel gene candidates and design/coordinate the necessary studies to measure the validity of developing these genes as Oncology Drug Discovery targets.CCR2 Antagonist anti-angiogenesis project - Successfully coordinated collaboration between key members of the Immunology CCR2 DWG and Oncology In vivo Group to measure the effect(s) of BMS CCR2 antagonist treatment of tumor bearing mice. Continued to monitor CCR2 Antagonist Program progress for Oncology applications.

Princeton, Nj

Mitotic Kinesin Inhibitor Full Phase DWG member - Enhanced drug discovery expertise as well as managerial skills by working with a diverse group of individuals to obtain data supporting Kinesin Inhibitor Program. Responsibilities included evaluating select small molecule Kinesin inhibitors in L-V Biology assays; designing assays to characterize chemotherapeutic resistant cell lines; determining Kinesin Inhibitor MOA through siRNA studies & acquiring tumor cell expression profiles following treatment with agents that affect Kinesin activity. Participated in decision process & communicated results to the DWG. BMS-Exploratory DWG member - Evaluated scientific and pharmaceutical applicability of pursuing nuclear pore sumo ligase as a drug discovery target and presented findings to the DWG. Efforts resulted in management selecting the target for further validation. Formulated and communicated strategy to understand mechanism of action of target inhibition using reagents and cell lines currently available in L-V Biology. Initiated siRNA validation studies to help drive Go/No Go decision for target selection.

Greater San Diego Area

Cloned and characterized the pathogenic properties of new Human Immunodeficiency Virus type 2 (HIV-2) strains.

Greater San Diego Area

Cloned and mapped the functional domains of Feline Immunodeficiency Virus (FIV)